Gold Prices Steady Ahead of Trump-Xi Meeting as Inflation and Oil Concerns Persist 
Asian Currencies Steady as Trump-Xi Summit, Inflation Concerns Boost Dollar 
BOJ Rate Hike Expectations Grow as Board Member Signals Hawkish Stance 
Oil Prices Slip as Strait of Hormuz Disruptions and U.S. Inventory Data Keep Markets on Edge 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility 
BlackRock-Led GCC Infrastructure Partnership Targets $30 Billion Investment 
Asian Currencies Hold Steady as Strong U.S. Inflation Data Boosts Dollar 
Asian Stocks Steady as Iran War Concerns Persist Ahead of Trump-Xi Summit 
Trump Says Iran Ceasefire ‘On Life Support’ as Oil Prices Surge Above $104 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Trump and Xi Temple of Heaven Visit Highlights Trade and Diplomacy Goals 
Alibaba Stock Surges After Strong Q4 Earnings Boosted by AI and Cloud Growth 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
GSK, a British pharmaceutical and biotech firm that was formerly known as Glaxo Smith Kline plc, announced that it had hired Julie Brown to be its new chief financial officer. The company said on Monday, Sept. 26, that the executive would formally join GSK next week.
According to Sky News, the move to recruit Brown is a strategy to form an all-female team of executives. It was reported that the newly-recruited CFO was poached by GSK from the Burberry Group PLC fashion company.
Brown will be replacing Iain Mackay, who is set to retire. He has been serving as GSK’s finance chief since 2019. The formation of an all-female team is very rare in the business, but the company is aiming for this with the recruitment of Brown.
Reuters reported that Brown is set to step down in April 2023 from Burberry after serving for more than five years as its CFO. She is a 60-year-old British woman who started working at the said fashion house in 2017. Prior to this, she worked at Smith & Nephew's medical device products manufacturing firm.
She also held an executive job role in AstraZeneca as interim group CFO and was appointed to senior roles at some of GSK’s rival companies. In addition, she was a non-executive director of Roche Holding Swiss healthcare group, but she is likely to step down after accepting the CFO role at GSK.
“I want to thank Iain for all he’s done for GSK, and for his leadership and support to our people. He has played a very significant role to help deliver the reshaping of GSK and to improve our operating and financial performance,” GSK’s chief executive officer, Emma Walmsley, said in a press release. “I am absolutely delighted that Julie will be joining the leadership team as his successor. Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector.”
The CEO added, “We also share a strong passion for people development, diversity, inclusion and sustainability. I am looking forward to working together to deliver progress for patients, shareholders and our people.”
